About Us
ACADIA Pharmaceuticals is a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders.
More »
News
February 01, 2010
ACADIA Pharmaceuticals to Present at the BIO CEO & Investor
Conference on February 8, 2010
November 09, 2009
ACADIA Pharmaceuticals Reports Third Quarter 2009 Financial Results
Product Candidates
We are focused on developing a portfolio consisting of four product candidates including pimavanserin, which is in Phase III development for the treatment of Parkinson's disease psychosis in collaboration with Biovail. In addition, we have a product candidate in Phase II for chronic pain and a product candidate in Phase I for glaucoma, both in collaboration with Allergan, and a program in IND-track development in collaboration with Meiji Seika.
Company Information
 |
Request Information » |
 |
Investor Webcasts » |
 |
Email Updates » |